Cynapsus Therapeutics Inc. (CYNA) Sets New 1-Year High at $40.25
Cynapsus Therapeutics Inc. (NASDAQ:CYNA)’s share price reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $40.25 and last traded at $40.20, with a volume of 209,763 shares. The stock had previously closed at $40.20.
A number of equities analysts recently issued reports on the stock. Janney Montgomery Scott downgraded shares of Cynapsus Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, September 1st. BMO Capital Markets reissued a “buy” rating and issued a $21.00 price objective on shares of Cynapsus Therapeutics in a report on Tuesday, July 19th. Finally, Noble Financial reissued a “buy” rating and issued a $50.00 price objective on shares of Cynapsus Therapeutics in a report on Tuesday, August 30th.
The firm’s 50-day moving average is $25.47 and its 200 day moving average is $16.79. The stock’s market cap is $499.05 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/cynapsus-therapeutics-inc-cyna-sets-new-1-year-high-at-40-25.html
Cynapsus Therapeutics (NASDAQ:CYNA) last announced its earnings results on Thursday, August 11th. The company reported $0.83 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.77) by $1.60. On average, analysts forecast that Cynapsus Therapeutics Inc. will post ($3.15) EPS for the current fiscal year.
About Cynapsus Therapeutics
Cynapsus Therapeutics Inc is a Canada-based specialty central nervous system (CNS) pharmaceutical company. It develops a sublingual thin film for the potential treatment for on-demand management of debilitating OFF episodes associated with Parkinson’s disease (PD). The Company completed a Phase two clinical trial for its product candidate, APL-130277, a sublingual formulation of apomorphine hydrochloride, or apomorphine.
Receive News & Ratings for Cynapsus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynapsus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.